High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma

Histopathology

Volumn 65, Issue 4, 2014, Pages 490-500

  Pedersen, Martin B ^a   Danielsen, Allan V ^a   Hamilton Dutoit, Stephen J ^a   Bendix, Knud ^a   Nørgaard, Peter ^b   Møller, Michael B ^c   Steiniche, Torben ^a   d'Amore, Francesco ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anaplastic large cell lymphoma; CD163; CD68; Immunohistochemistry; Macrophages; Prognosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD163 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; DISEASE FREE SURVIVAL; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MACROPHAGE; METABOLISM; MIDDLE AGED; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CELL SURFACE; YOUNG ADULT;

EID: 84911806284     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12407     Document Type: Article

References (50)

1. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66; 848-858.
2. Swerdlow S, Campo E, Harris NL et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissue. 4th ed. Lyon, France: IARC Press, 2008.
3. de Leval L, Gaulard P. Pathology and biology of peripheral T cell lymphomas. Histopathology 2011; 58; 49-68.
4. Piva R, Agnelli L, Pellegrino E et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J. Clin. Oncol. 2010; 28; 1583-1590.
5. Chiarle R, Simmons WJ, Cai H et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 2005; 11; 623-629.
6. ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJ. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003; 43; 462-469.
7. Lamant L, de Reyniès A, Duplantier MM et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109; 2156-2164.
8. Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. 2007; 117; 823-834.
9. Iqbal J, Weisenburger DD, Greiner TC et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115; 1026-1036.
10. Thompson MA, Stumph J, Henrickson SE et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum. Pathol. 2005; 36; 494-504.
11. Agnelli L, Mereu E, Pellegrino E et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 2012; 120; 1274-1281.
12. Salaverria I, Bea S, Lopez-Guillermo A et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br. J. Haematol. 2008; 140; 516-526.
13. Feldman AL, Dogan A, Smith DI et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011; 117; 915-919.
14. Liu C, Iqbal J, Teruya-Feldstein J et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood 2013; 122; 2083-2092.
15. Savage KJ, Harris NL, Vose JM et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111; 5496-5504.
16. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 2008; 26; 4124-4130.
17. Sibon D, Fournier M, Briere J et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J. Clin. Oncol. 2012; 30; 3939-3946.
18. Jensen TO, Schmidt H, Moller HJ et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J. Clin. Oncol. 2009; 27; 3330-3337.
19. Komohara Y, Hasita H, Ohnishi K et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011; 102; 1424-1431.
20. Lee CH, Espinosa I, Vrijaldenhoven S et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin. Cancer Res. 2008; 14; 1423-1430.
21. Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 2010; 362; 875-885.
22. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011; 96; 269-276.
23. Farinha P, Masoudi H, Skinnider BF et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106; 2169-2174.
24. Cai QC, Liao H, Lin SX et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med. Oncol. 2012; 29; 2317-2322.
25. Niino D, Komohara Y, Murayama T et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma (AITL). Pathol. Int. 2010; 60; 278-283.
26. Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk. Lymphoma 2011; 52; 46-52.
27. Lin ZX, Bai B, Cai QC et al. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med. Oncol. 2012; 29; 3522-3528.
28. Pedersen MB, Riber-Hansen R, Nielsen PS et al. Digital pathology for the validation of tissue microarrays in peripheral T-cell lymphomas. Appl. Immunohistochem. Mol. Morphol. 2014. in press.
29. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 2007; 25; 579-586.
30. Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat. Med. 2007; 26; 4505-4519.
31. Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations. Stata J. 2010; 10; 408-422.
32. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1; 307-310.
33. Sugaya M, Miyagaki T, Ohmatsu H et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J. Dermatol. Sci. 2012; 68; 45-51.
34. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66; 605-612.
35. Giorgio S. Macrophages: plastic solutions to environmental heterogeneity. Inflamm. Res. 2013; 62; 835-843.
36. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat. Rev. Immunol. 2010; 10; 453-460.
37. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008; 8; 958-969.
38. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 2011; 11; 750-761.
39. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006; 42; 717-727.
40. Cook J, Hagemann T. Tumour-associated macrophages and cancer. Curr. Opin. Pharmacol. 2013; 13; 595-601.
41. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am. J. Clin. Pathol. 2004; 122; 794-801.
42. Saito N, Pulford KA, Breton-Gorius J, Masse JM, Mason DY, Cramer EM. Ultrastructural localization of the CD68 macrophage-associated antigen in human blood neutrophils and monocytes. Am. J. Pathol. 1991; 139; 1053-1059.
43. DeNardo DG, Brennan DJ, Rexhepaj E et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1; 54-67.
44. d'Amore F, Relander T, Lauritzsen GF et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J. Clin. Oncol. 2012; 30; 3093-3099.
45. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93; 3913-3921.
46. Suzuki R, Kagami Y, Takeuchi K et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000; 96; 2993-3000.
47. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993; 329; 987-994.
48. Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116; 3418-3425.
49. von KA, Lotero A, Brune B. Etoposide and cisplatin induced apoptosis in activated RAW 264.7 macrophages is attenuated by cAMP-induced gene expression. Oncogene 1998; 17; 387-394.
50. Mehta RS, Smith RE. Hemophagocytic lymphohistiocytosis (HLH): a review of literature. Med. Oncol. 2013; 30; 740.